TABLE 3.
Multivariable analysis Cox regression for cancer‐specific survival in patients with LUAD specific organ metastases
| Variables | LUAD patients with specific organ metastases | Variable | LUAD patients with specific organ metastases | ||||
|---|---|---|---|---|---|---|---|
| N = 17 529 | Hazard ratio (95% CI) | P | n = 17 529 | Hazard ratio (95% CI) | P | ||
| N (%) | No. | ||||||
| Diagnosed years | T stage | ||||||
| 2010–2012 | 7835 (44.70%) | 1 | NA | T1 | 2343 (13.37%) | 1 | NA |
| 2013–2015 | 9694 (55.30%) | 0.91 (0.89–0.94) | <0.01 | T2 | 4798 (27.37%) | 1.17 (1.11–1.23) | <0.01 |
| Sex | T3 | 4472 (25.51%) | 1.18 (1.11–1.24) | <0.01 | |||
| Male | 8936 (50.98%) | 1 | NA | T4 | 5916 (33.75%) | 1.17 (1.11–1.23) | <0.01 |
| Female | 8593 (49.02%) | 0.81 (0.78–0.83) | <0.01 | N‐stage | |||
| Diagnosed age | N0 | 4040 (23.05%) | 1 | NA | |||
| 18–45 | 583 (3.33%) | 1 | NA | N1 | 1471 (8.39%) | 1.13 (1.06–1.20) | <0.01 |
| 46–70 | 10 908 (62.23%) | 1.39 (1.27–1.52) | <0.01 | N2 | 8086 (46.13%) | 1.27 (1.22–1.32) | <0.01 |
| >70 | 6038 (34.45%) | 1.63 (1.48–1.79) | <0.01 | N3 | 3932 (22.43%) | 1.35 (1.28–1.41) | <0.01 |
| Marital status | Metastatic organ no. | ||||||
| Married | 14 576 (83.15%) | 1 | NA | 1 | 10 507 (59.94%) | 1 | NA |
| Unmarried | 2953 (16.85%) | 1.05 (1.01–1.10) | 0.02 | 2 | 4899 (27.95%) | 1.28 (1.24–1.33) | <0.01 |
| Insurance, PRCDA | 3 | 1745 (9.95%) | 1.51 (1.43–1.59) | <0.01 | |||
| Yes | 4816 (27.47%) | 1 | NA | 4 | 378 (2.16%) | 1.65 (1.48–1.83) | <0.01 |
| No | 12 713 (72.53%) | 1.01 (0.97–1.04) | 0.70 | Surgery | |||
| Race, ethnicity | Yes | 571 (3.26%) | 1 | NA | |||
| White | 13 450 (76.73%) | 1 | NA | No | 16 958 (96.74%) | 1.82 (1.65–2.01) | <0.01 |
| American Indian | 94 (0.54%) | 0.89 (0.72–1.10) | 0.29 | Chemotherapy | |||
| Asian or PI | 1758 (10.03%) | 0.68 (0.64–0.71) | <0.01 | Yes | 10 600 (60.47%) | 1 | NA |
| Black | 2227 (12.70%) | 0.99 (0.95–1.04) | 0.72 | No | 6929 (39.53%) | 2.69 (2.60–2.79) | <0.01 |
| Laterality | Radiation | ||||||
| Left | 7169 (40.90%) | 1 | NA | Yes | 9794 (55.87%) | 1 | NA |
| Right | 10 360 (59.10%) | 1.03 (1.00–1.06) | 0.08 | No | 7735 (44.13%) | 0.97 (0.93–1.00) | 0.04 |
| Primary site | Chemotherapy and surgery | ||||||
| Upper lobe | 10 632 (60.65%) | 1 | NA | Yes | 2348 (13.39%) | 1 | NA |
| Middle lobe | 910 (5.19%) | 1.20 (1.11–1.30) | <0.01 | No | 15 181 (86.61%) | 1.01 (0.95–1.08) | 0.76 |
| Lower lobe | 5076 (28.96%) | 0.93 (0.86–1.00) | 0.04 | Radiation and surgery | |||
| Overlapping | 200 (1.14%) | 1.03 (0.99–1.06) | 0.13 | Yes | 2246 (12.81%) | 1 | NA |
| Main bronchus | 711 (4.06%) | 1.08 (0.93–1.24) | 0.32 | No | 15 283 (87.19%) | 1.17 (1.09–1.25) | <0.01 |
Abbreviations: CI, confidence interval; LUAD, lung adenocarcinoma; NA, not applicable; PI, pacific islander; PRCDA, purchased/referred care delivery area.